

### **Amendments to the Specification**

Page 1; change the title to: BENZO-OXADIAZOLES, -THIADIAZOLES and -1,4-DIAZINES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND A PROCESS FOR PREPARING THEM.

Please amend the paragraph beginning on Page 7, line 23 and ending on Page 8, line 2 as follows:

For the above-mentioned indications, the appropriate dosage will of course vary depending upon, for example, the compound employed, the host, the mode of administration and the nature and severity of the condition being treated. However, in general, satisfactory results in animals are indicated to be obtained at a daily dosage of from about 0.1 to about 100, preferably from about 0.5 to about 100 mg/kg animal body weight. In larger mammals, for example humans, an indicated daily dosage is in the range from ~~[[yout]]~~ about 1 to about 500, preferably from about 1 to about 300 mg of an agent of the invention, conveniently administered, for example, in divided doses up to four times a day or in sustained release form.

Please amend the paragraph beginning on Page 9, line 21 and ending on the last line of said page as follows:

4-Amino-5,7-dimethyl-2,1,3-benzothiadiazole (4 g) is added in portions to a 55%-dispersion of sodium hydride (2.72 g) in abs. tetrahydrofuran (50 ml) under an argon atmosphere. The mixture is stirred at 25-30° for 3 hours, then a solution ~~[[os 4,5-dichloro-2,5-dimethyl-pyrimidine]]~~ of 4,6-dichloro-2,5-dimethyl-pyrimidine (4 g) in abs. tetrahydrofuran (20 ml) is added in drops at 5° during 30 minutes. The reaction mixture is stirred at room temperature for 16 further hours, then ice water is carefully added. The resulting precipitate is washed with water and a few ml of methanol. After recrystallisation from methanol or cyclohexane, 4-(4-chloro-2,5-dimethyl-pyrimidin-6-yl)-amino-5,7-dimethyl-2,1,3-benzothiadiazole is obtained. Mp = 174-177°.